Iatrogenic pathology of the urinary bladder

Antonio Lopez-Beltran, Rodolfo Montironi, Maria R. Raspollini, Liang Cheng, George J. Netto

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Intravesical immunotherapy, chemotherapy, and neoadjuvant systemic chemotherapy are among the most frequent therapeutic procedures to treat malignancies of the urinary bladder. These treatment modalities produce reactive morphologic changes in the urothelium that can mimic urothelial carcinoma in situ, urothelial dysplasia or true invasive urothelial neoplasia. Mitomycin C used after transurethral resection of bladder tumor to reduce recurrences, BCG intravesical immunotherapy to treat high risk non-muscle invasive bladder cancer and urothelial carcinoma in situ, and platinum-based systemic chemotherapy to improve post-cystectomy disease-specific survival some of the causes of therapy related atypia in urinary bladder. In addition, a number of systemic drugs in use to treat other systemic diseases, such as cyclophosphamide used to treat certain auto-immune disorders or hematologic malignancies, or the anesthetics ketamine increasingly used as illegal recreational drug, may produce similarly relevant atypical changes in the urothelium, and therefore, need to be differentiated from intraepithelial neoplasia. Immunohistochemical approach to reactive urothelium from CIS using CK20, p53, and CD44 may also be of utility in the pos-therapy scenario.

Original languageEnglish (US)
JournalSeminars in Diagnostic Pathology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Urothelium
Urinary Bladder
Pathology
Carcinoma in Situ
Urinary Bladder Neoplasms
Drug Therapy
Immunotherapy
Neoplasms
Cystectomy
Immune System Diseases
Ketamine
Street Drugs
Mitomycin
Hematologic Neoplasms
Therapeutics
Mycobacterium bovis
Platinum
Cyclophosphamide
Anesthetics
Recurrence

Keywords

  • Atypia
  • Bladder
  • Chemotherapy
  • Flat lesions
  • Immunotherapy
  • Radiation therapy
  • Urothelium

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Lopez-Beltran, A., Montironi, R., Raspollini, M. R., Cheng, L., & Netto, G. J. (Accepted/In press). Iatrogenic pathology of the urinary bladder. Seminars in Diagnostic Pathology. https://doi.org/10.1053/j.semdp.2018.03.001

Iatrogenic pathology of the urinary bladder. / Lopez-Beltran, Antonio; Montironi, Rodolfo; Raspollini, Maria R.; Cheng, Liang; Netto, George J.

In: Seminars in Diagnostic Pathology, 01.01.2018.

Research output: Contribution to journalArticle

Lopez-Beltran, Antonio ; Montironi, Rodolfo ; Raspollini, Maria R. ; Cheng, Liang ; Netto, George J. / Iatrogenic pathology of the urinary bladder. In: Seminars in Diagnostic Pathology. 2018.
@article{bd609d3ae20b4e56be6e2cfce7891f79,
title = "Iatrogenic pathology of the urinary bladder",
abstract = "Intravesical immunotherapy, chemotherapy, and neoadjuvant systemic chemotherapy are among the most frequent therapeutic procedures to treat malignancies of the urinary bladder. These treatment modalities produce reactive morphologic changes in the urothelium that can mimic urothelial carcinoma in situ, urothelial dysplasia or true invasive urothelial neoplasia. Mitomycin C used after transurethral resection of bladder tumor to reduce recurrences, BCG intravesical immunotherapy to treat high risk non-muscle invasive bladder cancer and urothelial carcinoma in situ, and platinum-based systemic chemotherapy to improve post-cystectomy disease-specific survival some of the causes of therapy related atypia in urinary bladder. In addition, a number of systemic drugs in use to treat other systemic diseases, such as cyclophosphamide used to treat certain auto-immune disorders or hematologic malignancies, or the anesthetics ketamine increasingly used as illegal recreational drug, may produce similarly relevant atypical changes in the urothelium, and therefore, need to be differentiated from intraepithelial neoplasia. Immunohistochemical approach to reactive urothelium from CIS using CK20, p53, and CD44 may also be of utility in the pos-therapy scenario.",
keywords = "Atypia, Bladder, Chemotherapy, Flat lesions, Immunotherapy, Radiation therapy, Urothelium",
author = "Antonio Lopez-Beltran and Rodolfo Montironi and Raspollini, {Maria R.} and Liang Cheng and Netto, {George J.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1053/j.semdp.2018.03.001",
language = "English (US)",
journal = "Seminars in Diagnostic Pathology",
issn = "0740-2570",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Iatrogenic pathology of the urinary bladder

AU - Lopez-Beltran, Antonio

AU - Montironi, Rodolfo

AU - Raspollini, Maria R.

AU - Cheng, Liang

AU - Netto, George J.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Intravesical immunotherapy, chemotherapy, and neoadjuvant systemic chemotherapy are among the most frequent therapeutic procedures to treat malignancies of the urinary bladder. These treatment modalities produce reactive morphologic changes in the urothelium that can mimic urothelial carcinoma in situ, urothelial dysplasia or true invasive urothelial neoplasia. Mitomycin C used after transurethral resection of bladder tumor to reduce recurrences, BCG intravesical immunotherapy to treat high risk non-muscle invasive bladder cancer and urothelial carcinoma in situ, and platinum-based systemic chemotherapy to improve post-cystectomy disease-specific survival some of the causes of therapy related atypia in urinary bladder. In addition, a number of systemic drugs in use to treat other systemic diseases, such as cyclophosphamide used to treat certain auto-immune disorders or hematologic malignancies, or the anesthetics ketamine increasingly used as illegal recreational drug, may produce similarly relevant atypical changes in the urothelium, and therefore, need to be differentiated from intraepithelial neoplasia. Immunohistochemical approach to reactive urothelium from CIS using CK20, p53, and CD44 may also be of utility in the pos-therapy scenario.

AB - Intravesical immunotherapy, chemotherapy, and neoadjuvant systemic chemotherapy are among the most frequent therapeutic procedures to treat malignancies of the urinary bladder. These treatment modalities produce reactive morphologic changes in the urothelium that can mimic urothelial carcinoma in situ, urothelial dysplasia or true invasive urothelial neoplasia. Mitomycin C used after transurethral resection of bladder tumor to reduce recurrences, BCG intravesical immunotherapy to treat high risk non-muscle invasive bladder cancer and urothelial carcinoma in situ, and platinum-based systemic chemotherapy to improve post-cystectomy disease-specific survival some of the causes of therapy related atypia in urinary bladder. In addition, a number of systemic drugs in use to treat other systemic diseases, such as cyclophosphamide used to treat certain auto-immune disorders or hematologic malignancies, or the anesthetics ketamine increasingly used as illegal recreational drug, may produce similarly relevant atypical changes in the urothelium, and therefore, need to be differentiated from intraepithelial neoplasia. Immunohistochemical approach to reactive urothelium from CIS using CK20, p53, and CD44 may also be of utility in the pos-therapy scenario.

KW - Atypia

KW - Bladder

KW - Chemotherapy

KW - Flat lesions

KW - Immunotherapy

KW - Radiation therapy

KW - Urothelium

UR - http://www.scopus.com/inward/record.url?scp=85044292143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044292143&partnerID=8YFLogxK

U2 - 10.1053/j.semdp.2018.03.001

DO - 10.1053/j.semdp.2018.03.001

M3 - Article

JO - Seminars in Diagnostic Pathology

JF - Seminars in Diagnostic Pathology

SN - 0740-2570

ER -